Skip to main content

INCY

Stock
Health Care
Biotechnology

Performance overview

INCY Price
Price Chart

Forward-looking statistics

Beta
0.44
Risk
32.26%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Company info

SectorHealth Care
IndustryBiotechnology
Employees3K
Market cap$13.3B

Fundamentals

Enterprise value$10.8B
Revenue$4.4B
Revenue per employee
Profit margin0.48%
Debt to equity1.18

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.20
Dividend per share
Revenue per share$22.13
Avg trading volume (30 day)$138M
Avg trading volume (10 day)$133M
Put-call ratio

Macro factor sensitivity

Growth+3.4
Credit-1.4
Liquidity-0.8
Inflation+1.7
Commodities+1.4
Interest Rates-0.9

Valuation

Dividend yield0.00%
PEG Ratio11.15
Price to sales3.00
P/E Ratio11.15
Enterprise Value to Revenue2.45
Price to book3.62

Upcoming events

Next earnings dayApril 29, 2025
Next dividend day
Ex. dividend day

News

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.

Zacks Investment Research (July 1, 2025)
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).

Benzinga (March 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free